Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Lin L, et al. Among authors: bivona tg. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E748-57. doi: 10.1073/pnas.1320956111. Epub 2014 Feb 3. Proc Natl Acad Sci U S A. 2014. PMID: 24550319 Free PMC article.
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. Blakely CM, et al. Among authors: bivona tg. Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2. Cell Rep. 2015. PMID: 25843712 Free PMC article.
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. Hrustanovic G, et al. Among authors: bivona tg. Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24. Nat Med. 2015. PMID: 26301689 Free PMC article.
RAS signaling in ALK fusion lung cancer.
Hrustanovic G, Bivona TG. Hrustanovic G, et al. Among authors: bivona tg. Small GTPases. 2016;7(1):32-3. doi: 10.1080/21541248.2015.1131803. Epub 2016 Feb 22. Small GTPases. 2016. PMID: 26901483 Free PMC article.
Current Landscape of Targeted Therapy in Lung Cancer.
Mayekar MK, Bivona TG. Mayekar MK, et al. Among authors: bivona tg. Clin Pharmacol Ther. 2017 Nov;102(5):757-764. doi: 10.1002/cpt.810. Epub 2017 Sep 25. Clin Pharmacol Ther. 2017. PMID: 28786099 Review.
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. Jacobsen K, et al. Among authors: bivona tg. Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6. Nat Commun. 2017. PMID: 28871105 Free PMC article.
143 results